Clinical Trial Update: Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial assessing treatment of hot flashes induced by Leuprorelin 11.25 mg in men with prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Leuprorelin (leuprorelin)

Snippet

Sponsor: Takeda | Conditions: Adenocarcinoma, Prostate | Phase 3 | Status: COMPLETED